Michael Cory

Title: Michael Cory: Innovator in Carboxypeptidase A Enzymes

Introduction: Michael Cory is a notable inventor based in Chapel Hill, NC, who has made significant contributions to the field of biochemistry and molecular biology. With a total of 2 patents to his name, Cory's work focuses on the development of novel nucleic acids and enzymes that have the potential to advance therapeutic applications.

Latest Patents: Michael Cory's latest patents include "Nucleic acids encoding mutant human carboxypeptidase A enzymes" and "Cell-targeting molecule comprising a mutant human carboxypeptidase A." The first patent relates to nucleic acid molecules that encode a mutant variant of human carboxypeptidase A, as well as conjugates that target specific molecules in conjunction with these enzymes. The second patent highlights a cell-targeting molecule incorporating the mutant enzyme, which can enhance specificity and efficacy in therapeutic interventions.

Career Highlights: Michael Cory is currently employed at Glaxo Wellcome Inc., a leading company in pharmaceutical research and development. Throughout his career, he has applied his expertise to innovate solutions that impact the health and wellness sectors, bridging the gap between scientific research and practical applications.

Collaborations: Throughout his career, Cory has collaborated with distinguished colleagues such as Gary Keith Smith and Todd A. Blumenkopf. These collaborations have facilitated significant advancements in their respective fields and have contributed to the successful development of their patented technologies.

Conclusion: Michael Cory stands out as an inventor in the field of carboxypeptidase A enzymes, showcasing a commitment to innovation and collaboration. His patents not only reflect his expertise but also demonstrate a forward-thinking approach to biotechnology that can lead to important medical breakthroughs.